Artelo Biosciences (ARTLW) News Today → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free ARTLW Stock Alerts $0.02 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | markets.businessinsider.comArtelo Biosciences: Strong Buy Rating on Clinical Advancement and Solid FinancialsMay 13, 2024 | investorplace.comARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024May 8, 2024 | wsj.comArtelo Biosciences Inc.March 28, 2024 | uk.investing.comArtelo Biosciences Inc (ARTL)March 27, 2024 | markets.businessinsider.comBuy Rating on Artelo Biosciences: Strong Pipeline and Market PotentialMarch 25, 2024 | investorplace.comARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023March 25, 2024 | benzinga.comRecap: Artelo Biosciences Q4 EarningsMarch 12, 2024 | finance.yahoo.comArtelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeFebruary 15, 2024 | finance.yahoo.comArtelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thJanuary 23, 2024 | finance.yahoo.comArtelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral NeuropathyNovember 30, 2023 | finance.yahoo.comArtelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyNovember 9, 2023 | finance.yahoo.comArtelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain CancersOctober 4, 2023 | finance.yahoo.comPrincipal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and CachexiaSeptember 13, 2023 | finance.yahoo.comArtelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20thSeptember 7, 2023 | finance.yahoo.comArtelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12September 6, 2023 | finance.yahoo.comArtelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12thAugust 10, 2023 | finance.yahoo.comArtelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 19, 2023 | finance.yahoo.comArtelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023July 10, 2023 | finance.yahoo.comArtelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11June 28, 2023 | finance.yahoo.comArtelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society SymposiumJune 26, 2023 | msn.comArtelo Biosciences Presents Groundbreaking Research At Annual CBD Symposium In CanadaJune 26, 2023 | finance.yahoo.comArtelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society SymposiumJune 7, 2023 | finance.yahoo.comArtelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society SymposiumMarch 31, 2023 | finance.yahoo.comArtelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business UpdateFebruary 2, 2023 | finance.yahoo.comArtelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossJanuary 26, 2023 | finance.yahoo.comArtelo Biosciences to Present at Sequire Biotechnology Conference on February 2ndSeptember 1, 2022 | uk.finance.yahoo.comArtelo Biosciences, Inc. (ARTLW)August 16, 2022 | marketwatch.comArtelo Biosciences Shares Up on Promising Antianxiety ResearchAugust 9, 2022 | finance.yahoo.comArtelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateJuly 19, 2022 | finance.yahoo.comArtelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossJuly 14, 2022 | finance.yahoo.comeFFECTOR Therapeutics, Inc. (EFTRW)June 24, 2022 | finance.yahoo.comArtelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, IrelandJune 13, 2022 | benzinga.comArtelo Biosciences (NASDAQ:ARTLW), Short Interest ReportJune 1, 2022 | finance.yahoo.comArtelo Biosciences to Present at the LD Micro Invitational XII on June 7thMay 13, 2022 | finance.yahoo.comArtelo Biosciences to Present at MicroCap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16thMay 12, 2022 | finance.yahoo.comArtelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTLW and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. ARTLW Media Mentions By Week ARTLW Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTLW News Sentiment▼1.870.76▲Average Medical News Sentiment ARTLW News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTLW Articles This Week▼10▲ARTLW Articles Average Week Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTLW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DRTSW News Today BCTXW News Today EFTRW News Today FBIOP News Today GOVXW News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTLW) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
